In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors. Standard of care for grade II and III glioma consists of resection. For patients with tumors that require postoperative treatment, radiotherapy and chemotherapy are recommended. Trials in newly diagnosed grade II and III glioma have shown survival benefit of the addition of chemotherapy to radiotherapy compared with initial treatment with radiotherapy alone; both temozolomide and PCV have been shown to improve survival.

Additional Metadata
Keywords 1p/19q codeletion, Anaplastic, Astrocytoma, Bevacizumab, IDH, Oligodendroglioma, PCV, Temozolomide
Persistent URL dx.doi.org/10.1016/j.ncl.2018.04.005, hdl.handle.net/1765/114109
Journal Neurologic Clinics
Citation
van den Bent, M.J, & Chang, S.M. (2018). Grade II and III Oligodendroglioma and Astrocytoma. Neurologic Clinics (Vol. 36, pp. 467–484). doi:10.1016/j.ncl.2018.04.005